CA2977401A1 - Small molecules that enable cartilage rejuvenation - Google Patents

Small molecules that enable cartilage rejuvenation Download PDF

Info

Publication number
CA2977401A1
CA2977401A1 CA2977401A CA2977401A CA2977401A1 CA 2977401 A1 CA2977401 A1 CA 2977401A1 CA 2977401 A CA2977401 A CA 2977401A CA 2977401 A CA2977401 A CA 2977401A CA 2977401 A1 CA2977401 A1 CA 2977401A1
Authority
CA
Canada
Prior art keywords
substituted
unsubstituted
nhc
halogen
hydrogen
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA2977401A
Other languages
English (en)
French (fr)
Inventor
Denis EVSEENKO
Benjamin J. Van Handel
Varghese John
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of California, San Diego
Original Assignee
University of California, San Diego
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of California, San Diego filed Critical University of California, San Diego
Publication of CA2977401A1 publication Critical patent/CA2977401A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D277/38—Nitrogen atoms
    • C07D277/42—Amino or imino radicals substituted by hydrocarbon or substituted hydrocarbon radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CA2977401A 2015-02-27 2016-02-29 Small molecules that enable cartilage rejuvenation Abandoned CA2977401A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562126010P 2015-02-27 2015-02-27
US62/126,010 2015-02-27
PCT/US2016/020126 WO2016138533A2 (en) 2015-02-27 2016-02-29 Small molecules that enable cartilage rejuvanation

Publications (1)

Publication Number Publication Date
CA2977401A1 true CA2977401A1 (en) 2016-09-01

Family

ID=56789264

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2977401A Abandoned CA2977401A1 (en) 2015-02-27 2016-02-29 Small molecules that enable cartilage rejuvenation

Country Status (8)

Country Link
US (2) US11072592B2 (enExample)
EP (1) EP3262040A4 (enExample)
JP (1) JP2018508513A (enExample)
KR (1) KR20170122788A (enExample)
CN (1) CN107531687A (enExample)
AU (1) AU2016224975B2 (enExample)
CA (1) CA2977401A1 (enExample)
WO (1) WO2016138533A2 (enExample)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20170122788A (ko) 2015-02-27 2017-11-06 더 리젠츠 오브 더 유니버시티 오브 캘리포니아 연골 재생을 가능하게 하는 소분자
EP3493803A4 (en) * 2016-08-05 2020-04-22 The Regents of The University of California GP130 MODULATORS
US10828289B2 (en) 2016-08-26 2020-11-10 The Regents Of The University Of California Hair follicle stem cell activation and hair growth
EP3758700B1 (en) 2018-02-28 2024-07-31 University of Southern California Compositions for modulating inflammatory and degenerative disorders
CN112877283A (zh) * 2021-02-10 2021-06-01 安徽农业大学 一种鸡原代软骨细胞分离培养及鉴定的方法
CN114276999A (zh) * 2022-03-03 2022-04-05 中日友好医院(中日友好临床医学研究所) 黑素瘤细胞株及其制备方法
WO2023205366A1 (en) * 2022-04-20 2023-10-26 Carthronix, Inc. Small molecule modulators of gp130 signaling pathways
WO2026127686A1 (ko) * 2024-12-11 2026-06-18 주식회사 프리모테라 당단백질130 억제제로서 신규한 화합물

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4911920A (en) 1986-07-30 1990-03-27 Alcon Laboratories, Inc. Sustained release, comfort formulation for glaucoma therapy
FR2588189B1 (fr) 1985-10-03 1988-12-02 Merck Sharp & Dohme Composition pharmaceutique de type a transition de phase liquide-gel
DK0495421T3 (da) 1991-01-15 1996-12-09 Alcon Lab Inc Anvendelse af carragenaner i topiske ophthalmiske sammensætninger
US5212162A (en) 1991-03-27 1993-05-18 Alcon Laboratories, Inc. Use of combinations gelling polysaccharides and finely divided drug carrier substrates in topical ophthalmic compositions
US6309853B1 (en) 1994-08-17 2001-10-30 The Rockfeller University Modulators of body weight, corresponding nucleic acids and proteins, and diagnostic and therapeutic uses thereof
CA2397661C (en) 2000-03-01 2012-01-03 Janssen Pharmaceutica N.V. 2,4-disubstituted thiazolyl derivatives
JP2002020286A (ja) * 2000-06-30 2002-01-23 Sumitomo Pharmaceut Co Ltd 骨・軟骨疾患治療剤
HUP0401748A3 (en) * 2001-08-13 2011-03-28 Janssen Pharmaceutica Nv 2-amino-4,5-trisubstituted thiazolyl derivatives, process for their preparation and pharmaceutical compositions containing them
CN102584813B (zh) * 2003-05-14 2016-07-06 Ngc药物公司 化合物及其在调节淀粉样蛋白β中的用途
WO2005033288A2 (en) * 2003-09-29 2005-04-14 The Johns Hopkins University Hedgehog pathway antagonists
EP1860098B1 (en) * 2005-03-16 2012-11-14 Toyama Chemical Co., Ltd. Novel anthranilic acid derivative or salt thereof
AU2006244203B2 (en) * 2005-05-09 2012-05-03 Achillion Pharmaceuticals, Inc. Thiazole compounds and methods of use
JP2008543754A (ja) 2005-06-09 2008-12-04 メルク エンド カムパニー インコーポレーテッド チェックポイントキナーゼの阻害剤
AU2006290814B2 (en) * 2005-09-13 2012-06-07 Janssen Pharmaceutica N.V. 2-aniline-4-aryl substituted thiazole derivatives
US20090280483A1 (en) * 2005-11-22 2009-11-12 Toshio Kitamura Methods for Screening Interleukin-6 (IL-6) Signal Transduction Inhibitors
EP2007393B1 (en) * 2006-04-07 2013-08-21 Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College Thiazole and thiophene analogues, and their use in treating autoimmune diseases and cancers
EA200901573A1 (ru) * 2007-05-22 2010-04-30 Ачиллион Фармасьютикалз, Инк. Гетероарилзамещенные тиазолы
US9315449B2 (en) * 2008-05-15 2016-04-19 Duke University Substituted pyrazoles as heat shock transcription factor activators
CN103059014B (zh) 2011-10-21 2016-05-18 北京韩美药品有限公司 新型杂芳基氨基衍生物
CN103130792B (zh) * 2011-11-30 2016-05-04 正大天晴药业集团股份有限公司 一种2-氨基噻唑类化合物
ES2684776T3 (es) * 2013-01-18 2018-10-04 Bristol-Myers Squibb Company Ftalazinonas e isoquinolinonas como inhibidores de ROCK
US20150045353A1 (en) * 2013-08-09 2015-02-12 Neurogenetic Pharmaceuticals, Inc. Formulations containing gamma secretase modulators, methods for preparation and delivery thereof
KR20170122788A (ko) 2015-02-27 2017-11-06 더 리젠츠 오브 더 유니버시티 오브 캘리포니아 연골 재생을 가능하게 하는 소분자

Also Published As

Publication number Publication date
JP2018508513A (ja) 2018-03-29
CN107531687A (zh) 2018-01-02
WO2016138533A3 (en) 2016-12-01
WO2016138533A2 (en) 2016-09-01
US20180244638A1 (en) 2018-08-30
AU2016224975A1 (en) 2017-09-07
EP3262040A2 (en) 2018-01-03
US11247974B2 (en) 2022-02-15
KR20170122788A (ko) 2017-11-06
US11072592B2 (en) 2021-07-27
EP3262040A4 (en) 2018-09-12
AU2016224975B2 (en) 2020-10-22
US20190169141A1 (en) 2019-06-06

Similar Documents

Publication Publication Date Title
US11247974B2 (en) Small molecules that enable cartilage rejuvenation
US20220016110A1 (en) Compositions for the mobilization, homing, expansion and differentiation of stem cells and methods of using the same
Chen et al. Dedifferentiation of lineage-committed cells by a small molecule
EP3384007B1 (en) Improved methods for reprograming non-pluripotent cells into pluripotent stem cells
US9982237B2 (en) Compositions and methods for reprograming non-pluripotent cells into pluripotent stem cells
TW201843140A (zh) 6-6稠合雙環雜芳基化合物及其作為lats抑制劑之用途
Huang et al. Overcoming challenges in engineering large, scaffold-free neocartilage with functional properties
KR20240008354A (ko) 인간 과립구-대식세포 전구체의 확장 방법 및 그의 적용
CN102787092A (zh) 培养基、细胞培养用试剂盒及细胞培养方法
JPWO2017110425A1 (ja) 肝疾患治療剤及び肝疾患を治療する方法
CA3154084A1 (en) Feeder-based and feeder-free stem cell culture systems for stratified epithelial stem cells, and uses related thereto
KR20250106741A (ko) 화학적 재프로그래밍 방법 및 다능성 줄기세포
Bell et al. Distal lung organoids derived from adult stem cells as novel tools in deciphering mechanisms of lung regeneration, infection, and cancer
WO2022149616A1 (ja) ネフロン前駆細胞を拡大培養するための培地、ネフロン前駆細胞を拡大培養する方法、腎臓オルガノイドの製造方法
Wang et al. miR‑210 enhances mesenchymal stem cell‑modulated neural precursor cell migration
CA3034460A1 (en) Hair follicle stem cell activation and hair growth
Zhao et al. Absent, Small, or Homeotic 2-Like–Mediated H3K4 Methylation and Nephrogenesis
Swiderski et al. The Field of Hair Cell Regeneration Is Ready for Input from Genomics and Epigenetics
Aphkhazava et al. Integrated Cell Engineering and Data-Driven Regenerative Therapeutics: Convergence of Stem Cell Technologies, Exosome Biology, Aging Interventions, and Clinical Big Data Analytics
Sanyal et al. Targeting RARβ With a Stable Retinoic Acid Mimic Promotes Neurite Outgrowth, Neurogenesis, and Behavioral Recovery
HK1214143B (en) Compositions for the mobilization, homing, expansion and differentiation of stem cells and methods of using the same
Badowska-Kozakiewicz et al. Cancer stem cells–a new chance for successful treatment of cancer
NZ712630B2 (en) Compositions for the mobilization, homing, expansion and differentiation of stem cells and methods of using the same
Saunders II Epigenetic Modifications in Reactivation of Endogenous Cyclin A2

Legal Events

Date Code Title Description
FZDE Discontinued

Effective date: 20220525